Grace Therapeutics GRCE 深 沪
等待开盘 11-06 09:30:00 美东时间
1.78
-0.030
-1.66%
华盛通- 最 高1.9004
- 今 开1.81
- 成交量 9.71万股
- 最 低 1.75
- 昨 收 1.81
- 总市值 3.74万
- 52周最高 5.18
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 1.67
- 委 比 -70.94%
- 总股本 2.10万
- 历史最高 2016.00
- 量 比 0.87
- 振 幅 8.31%
- 历史最低 1.67
- 每 手 1
- 风险率 0.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
Grace Therapeutics, Inc. announced its participation in upcoming healthcare industry and investor conferences in November 2026. CEO Prashant Kohli will attend BIO-Europe 2026 in Cologne, Germany, and the Craig-Hallum 17th Annual Alpha Select Conference in New York. The company is focused on advancing GTx-104, an IV infusion targeting aSAH, which has received FDA Orphan Drug Designation and is supported by 52 granted and pending patents.
11-05 13:00
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
Grace Therapeutics' CEO, Prashant Kohli, will present at the H.C. Wainwright Global Investment Conference on September 14-16, 2026, in New York. His presentation will be available online starting September 11, and he will meet with investors during the event. Grace Therapeutics is a biopharma company developing GTx-104, an IV infusion for treating aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening condition. GTx-104 has receiv...
09-03 12:00
Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per share from the same period last year.
08-13 20:23
Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ...
07-28 19:06
Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.15) by 60 percent. This is a 160 percent decrease over earnings of $0.10 per share from the same period last year.
06-18 21:43
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Required; Intends To Resubmit Application Following Resolution Of Cited Items
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical DataCompany Intends to Resubmit
04-24 01:17
Grace Therapeutics Announces Acceptance Of Abstract Highlighting Results From STRIVE-ON Phase 3 Safety Trial For Presentation At 2026 American Academy of Neurology Meeting, April 18-22
The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:Session: S21: Neurocritical CareDate: April 21,
04-14 20:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Lunai Bioworks (NASDAQ:LNAI) stock moved upwards by 47.2% to $0.41 dur...
04-08 01:05
Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.28) by 50 percent. This is a 61.11 percent increase over losses of $(0.36) per share from
02-12 21:11
